United States Urinary Tract Infection Testing Market

The United States Urinary Tract Infection Testing Market by Product Type (Instruments and Kits {Laboratory Test Kits and Home Test Kits}), Test Type (Urinalysis and Urine Cultures), and End-User (Hospital, Diagnostic Labs, and Others), is expected to grow at a steady CAGR forecast till 2032 owing to the increasing urinary tract infection and risk factors associated with urinary tract infections in the United States, rising geriatric population in the United States, increasing product development activities in the U.S.

The United States urinary tract infection testing market was valued at USD 238.21 million in 2024, growing at a CAGR of 6.23% during the forecast period from 2025 to 2032 to reach USD 385.82 million by 2032. The growing risk factors associated with urinary tract infections (UTIs) in the United States, such as diabetes, obesity, and lifestyle-related issues, are driving the demand for efficient UTI testing solutions, fueling market growth. The rising geriatric population, which is more susceptible to UTIs due to weakened immune systems and age-related physiological changes, further contributes to the increasing need for reliable diagnostic tools. Additionally, the surge in product development activities by companies in the U.S., including the introduction of rapid diagnostic kits, point-of-care testing devices, and advanced molecular diagnostics, enhances the accessibility and accuracy of UTI testing. Together, these factors are propelling the growth of the UTI testing market in the United States by addressing the growing healthcare needs and improving patient outcomes during the forecast period from 2025 to 2032.

United States Urinary Tract Infection Testing Market Dynamics:

According to the National Institute of Health (NIH) data in 2023, over 10% of women in the United States are diagnosed with a UTI annually, with more than 60% of women experiencing at least one UTI in their lifetime.

Additionally, data from the Office on Women's Health in 2021 revealed that over half of women in the U.S. suffered from a UTI at some point in their lives. 

Similarly, data from the Centers for Disease Control and Prevention (CDC) in 2024 highlighted that UTIs are the most common healthcare-associated infection, accounting for more than 30% of all infections reported by acute care hospitals. This growing incidence is pushing healthcare providers to adopt advanced diagnostic tools, including rapid tests, point-of-care devices, and molecular diagnostics, to ensure effective treatment and management. Consequently, the escalating UTI burden is propelling innovation and investment in the UTI testing market, fostering its overall expansion.

According to data provided by the Centers for Disease Control and Prevention 2023, it was estimated that 29.7 million people, which accounts for 8.9% of the total population in the United States were diagnosed with diabetes in the year 2021. Patients with diabetes are more prone to urinary tract infections due to frequent urination and high blood sugar levels. The high sugar level provides a favorable growth environment to the pathogens thus leading to urinary tract infections.

One of the key factors contributing to the growth of the urinary tract infection testing market in the United States is the increasing number of product developments and launches related to urinary tract infection testing in the region. In October 2023, Pathnostics announced that its advanced test for urinary tract infections (UTIs) had gained approval from the New York State Department of Health. The approval broadens patient access to the company's Guidance® UTI test, which enables rapid diagnosis and precise treatment of complicated, recurrent, and persistent UTIs.

Thus, the factors mentioned above are expected to boost the overall market of United States urinary tract infection testing during the forecast period from 2025 to 2032.

However, increasing preference for self-medication the availability of over-the-counter (OTC) antibiotics and poor diagnostic efficacy of urinary tract infection testing products leading to faulty results may hinder the future market of United States urinary tract infection market during the forecasted period.

United States Urinary Tract Infection Testing Market Segment Analysis:

United States Urinary Tract Infection Testing Market by Product Type (Instruments and Kits {Laboratory Test Kits and Home Test Kits}), Test Type (Urinalysis and Urine Cultures), and End-User (Hospital, Diagnostic Labs, and Others)

The laboratory test kits segment of the Kits category in the United States urinary tract infection testing market is estimated to dominate the market with a market share of 56.94% in 2024. This can be attributed to the significance of laboratory test kits in the determination of a urinary tract infection in labs and, the presence of key products, among others during the forecast period. Laboratory test kits are specially manufactured for use in labs, which are handled by clinicians and diagnostic specialists in a controlled environment, to accurately detect the presence of a UTI. Since they are used by clinical practitioners, laboratory reagents and kits often have high quality, thus ensuring high accuracy in diagnosis. 

In addition, laboratory sample collection and testing is more reliable and efficient due to the presence of technicians, who also facilitate the appropriate transport and storage of specimens before laboratory testing, if needed. Thus, to accurately diagnose the microbe and the presence of UTI, only high-quality reagents and kits are manufactured for laboratory disease testing. For example, The Applied Biosystems TrueMark Urinary II Plus Combo Kit, by Thermofisher Scientific Inc. uses QuantStudio real-time PCR devices to provide an end-to-end workflow for numerous common infectious disease areas while achieving molecular detection with this technology. Urinary disease-causing bacteria could be quickly and accurately detected and classified with the use of the QuantStudio system in conjunction with the TrueMark panel. The TrueMark Urinary II Plus panel consists of duplexed TaqMan assays that use real-time PCR to detect Corynebacterium riegelii, Enterobacter aerogenes, Aerococcus urinae, Proteus vulgaris, Acinetobacter baumannii, Actinobaculum schaalii, Enterococcus faecalis, Streptococcus agalactiae, and an internal control.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of the United States urinary tract infection testing market.

United States Urinary Tract Infection Testing Market Key Players:

Some of the key market players operating in the United States urinary tract infection testing market include Thermo Fisher Scientific Inc., F. Hoffman-La Roche Ltd., Bio-Rad Laboratories, Inc., Danaher Corporation, Szio +, Cardinal Health, Sysmex Corporation, Seimens Healthineers, Abbott, Laboratory Corporation of America Holdings, and others.

Recent Developmental Activities in the United States Urinary Tract Infection Testing Market:

• In January 2024, Vivoo launched its at-home digital Urinary Tract Infection (UTI) test. The latest UTI test launched by Vivoo utilizes advanced deep-learning image processing technology to analyze test results. 
• In May 2023, The University of Texas at Dallas developed a prototype diagnostic sensor capable of confirming urinary tract infections (UTIs), eliminating the need to wait for 24 to 48 hours for laboratory test results. 

Key Takeaways From the United States Urinary Tract Infection Testing Market Report Study

• Market size analysis for current United States urinary tract infection testing size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the United States urinary tract infection testing market.
• Various opportunities available for the other competitors in the United States urinary tract infection testing market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current United States urinary tract infection testing market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for United States urinary tract infection testing market growth in the coming future?

Target Audience Who Can be Benefited from this United States Urinary Tract Infection Testing Market Report Study

• United States Urinary Tract Infection testing product providers
• Research organizations and consulting companies 
• United States Urinary Tract Infection Testing-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in United States urinary tract infection testing 
• Various end-users who want to know more about the United States urinary tract infection testing market and the latest technological developments in the United States urinary tract infection testing market.

Frequently Asked Questions for the United States Urinary Tract Infection Testing Market:

1. What is urinary tract infection testing?

• A urinary tract infection (UTI) is a common bacterial infection that can affect various parts of the urinary system. It typically involves the urethra (urethritis), bladder (cystitis), or kidneys (pyelonephritis).

2. What is the market for United States urinary tract infection testing?

• The United States urinary tract infection testing market was valued at USD 238.21 million in 2024, growing at a CAGR of 6.23% during the forecast period from 2025 to 2032 to reach USD 385.82 million by 2032. 

3. What are the drivers for the United States urinary tract infection testing market?

• The growing risk factors associated with urinary tract infections (UTIs) in the United States, such as diabetes, obesity, and lifestyle-related issues, are driving the demand for efficient UTI testing solutions, fueling market growth. The rising geriatric population, which is more susceptible to UTIs due to weakened immune systems and age-related physiological changes, further contributes to the increasing need for reliable diagnostic tools. Additionally, the surge in product development activities by companies in the U.S., including the introduction of rapid diagnostic kits, point-of-care testing devices, and advanced molecular diagnostics, enhances the accessibility and accuracy of UTI testing. Together, these factors are propelling the growth of the UTI testing market in the United States by addressing the growing healthcare needs and improving patient outcomes during the forecast period from 2025 to 2032.

4. Who are the key players operating in the United States urinary tract infection testing market?

• Some of the key market players operating in the United States urinary tract infection testing are Thermo Fisher Scientific Inc., F. Hoffman-La Roche Ltd., Bio-Rad Laboratories, Inc., Danaher Corporation, Szio +, Cardinal Health, Sysmex Corporation, Seimens Healthineers, Abbott, Laboratory Corporation of America Holdings, and others.